PSTI News Alert Pluristem Therapeutics (PSTI) 2.46 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pluristem Therapeutics (PSTI) 2.46 $PSTI

New Published Data Show Pluristem's PLX Cells Protect Neurons
GlobeNewswire - Mon Dec 22, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today that a study of PLacental eXpanded (PLX) cells was accepted for publication in the February, 2015 issue of Biochimica et Biophysica Acta Molecular Cell Research. The study results show that PLX cells protect PC12 cells - an established model of various nerve cells including dopaminergic neurons - from death after oxygen and glucose deprivation. The protective effects of PLX cells were strongly correlated with the secretion of interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF), which are known to have neuroprotective effects in humans with injuries to the nervous system that can occur after events such as a stroke.
PSTI: 2.46 (unch)

When Considering Cell Therapy Investments - Not All Cells Are the Same
ACCESSWIRE - Thu Dec 18, 9:14AM CST
LOS ANGELES, CA / ACCESSWIRE / December 18, 2014 / BioMedReports.com's editor, Dusty Garza, spoke with Pluristem Therapeutics' (NASDAQ STI) CEO, Zami Aberman, a leading developer of placenta-based cell therapy products, regarding clear differentiators between cell therapies and why the cell manufacturing process is key. The company recently launched their second cell therapy product candidate, PLX-RAD cells for the treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation.
PSTI: 2.46 (unch)

Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)

Intermittent Claudication - Pipeline Review, H2 2013
M2 - Mon Dec 15, 3:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/59bmx9/intermittent) has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2013" report to their offering. 'Intermittent Claudication - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: - Nissan Chemical Industries, Ltd. - Sangamo BioSciences, Inc. - Rigel Pharmaceuticals, Inc. - Sigma-Tau S.p.A. - Cytokinetics, Incorporated - Cytomedix, Inc. - Pluristem Therapeutics Inc. - LTT Bio-Pharma Co., Ltd. - Taisho Toyama Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/59...termittent
CYTK: 5.87 (+0.35), PSTI: 2.46 (unch), SGMO: 14.20 (+0.14), RIGL: 2.22 (+0.02)

Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:01AM CST
Pluristem Therapeutics has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
PSTI: 2.46 (unch)

Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.46 (unch)

Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
GlobeNewswire - Thu Dec 04, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem. The medical center's Department of Bone Marrow Transplantation and Cancer Immunotherapy, headed by Professor Reuven Or, will use preclinical models to assess the potential efficacy of PLX-RAD cells for treatment and prevention of hematological deficiencies and complications of bone marrow and umbilical cord blood transplantation. PLX-RAD cells are Pluristem's second cell therapy product candidate.
PSTI: 2.46 (unch)

Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 140.33 (-0.22), PSTI: 2.46 (unch), EXEL: 1.29 (-0.01)

Pluristem wins patent for 3D cell expansion technology in Singapore
M2 - Mon Dec 01, 7:22AM CST
Cell therapy products company Pluristem Therapeutics (NasdaqCM STI) (Tel Aviv STI.TA) reported on Monday the receipt of the patent titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy" in Singapore.
PSTI: 2.46 (unch)

Pluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology
GlobeNewswire - Mon Dec 01, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today it has been granted a patent in Singapore titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy."
PSTI: 2.46 (unch)

Pluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences
GlobeNewswire - Tue Nov 25, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today that Dr. Ohad Karnieli, the Company's vice president of development and manufacturing, will present at two scientific conferences on the latest advancements in large-scale cell therapy manufacturing.
PSTI: 2.46 (unch)

Pluristem posts 1Q loss
Automated Insights - Fri Nov 21, 6:15AM CST
HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Friday reported a loss of $5.9 million, or 9 cents per share, in its fiscal first quarter.
PSTI: 2.46 (unch)

Pluristem wins patents in Australia and New Zealand for placental cells for treating orthopedic, nerve injury and neurodegenerative diseases
M2 - Wed Nov 12, 6:25AM CST
Placenta cell therapy company Pluristem Therapeutics (NasdaqCM STI) (NasdaqCM STI.TA) disclosed on Wednesday the receipt of a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications.
PSTI: 2.46 (unch)

Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications
GlobeNewswire - Wed Nov 12, 2:35AM CST
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE STI), a leading developer of placenta-based cell therapy products, announced today that it has been granted a patent in both Australia and New Zealand for the use of a specified population of placental cells for treating several medical indications. The patent, titled "Adherent cells from placenta and use of same in disease treatment" has been issued in Australia, Patent No. 2010322808, and in New Zealand, Patent No. 600651.
PSTI: 2.46 (unch)

Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014
GlobeNewswire - Mon Nov 10, 2:00AM CST
London Regenerative Medicine Network Meeting
PSTI: 2.46 (unch)

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 340.89 (+5.13), PCYC: 121.84 (+1.15), PSTI: 2.46 (unch), NBS: 3.27 (+0.02), ALDR: 25.67 (+0.43), IDRA: 3.89 (+0.02), SGEN: 31.10 (-0.14), JAZZ: 165.33 (+1.83), ALXN: 181.96 (+3.09), KMDA: 3.57 (-0.03), ATHX: 1.30 (-0.03), NVS: 93.91 (+0.66)

Pluristem Therapeutics Developing Off-The-Shelf Cell Therapy to Cure Blood Cancers and Treat Radiation Sickness
ACCESSWIRE - Wed Nov 05, 7:40AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Innovation is the root of Pluristem Therapeutics's (PSTI:NASDAQ) technology, and its latest offering, PLX-RAD cells represent a new line of allogenic off-the-shelf therapy with two distinct and vital applications - bone marrow transplant (BMT) and acute radiation syndrome (ARS). PLX-RAD cells are specifically engineered to treat blood cancers and restore healthy bone marrow function following chemotherapy, radiation therapy, and radiation exposure resulting from a nuclear or terrorist dirty bomb.
PSTI: 2.46 (unch)

The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:21AM CDT
The Spectranetics Corporation (SPNC) was a big mover last session, as the company saw its shares soar by over 13% on the day.
SPNC: 34.50 (+0.59), VRX: 140.33 (-0.22), PSTI: 2.46 (unch), MYL: 56.97 (+0.39)

Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases
GlobeNewswire - Mon Oct 27, 2:59AM CDT
Pluristem Therapeutics Inc. (Nasdaq STI) (TASE LTR), a leading developer of placenta-derived cell therapy products, announced today that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental eXpanded (PLX)-RAD cells. The study will evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation.
PSTI: 2.46 (unch)

Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.46 (unch), UTHR: 130.22 (+2.40), OSIR: 14.87 (+0.13), ATHX: 1.30 (-0.03)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 120

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Teva’s R&D Exit Puts Disclosure Questions in Focus

Updated Category News Views 114

An abrupt departure in the drug business is never just an HR memo. Teva Pharmaceutical Industries shares reportedly dropped about 8.74% after Eric Hughes, the company’s executive vice president of Global R&D and chief medical officer, left effective immediately. That kind of move rattles investors because R&D leadership is not decorative furniture at a pharmaceutical...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 104

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
Surf City Seasons Put Vacation Rental Timing in Focus

Updated Category News Views 42

Summer’s Calendar Does the Talking School bells, not seagulls, appear to set the pace for Surf City’s rental market. Chris Rackley’s seasonal guide makes a pretty grounded point: the “best” time to visit Surf City, North Carolina, is not some universal magic week on a postcard. It depends on whether a traveler needs peak beach weather, wants elbow room, or...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading

Top 5 Most Recently Viewed Articles

Alphabet's Q2 Earnings: AI Insights and Market Reactions Await

Updated Category News Views 187

Alphabet's Q2 Earnings Report: A Focus on AI Growth Alphabet (NASDAQ: GOOGL), the parent company of Google, is poised to release its second quarter earnings soon. Many analysts and investors are keenly awaiting details that might reveal how the company’s artificial intelligence (AI) endeavors are transforming into tangible revenue streams. With the surge in interest...

Continue Reading
Join the Class Action Against Dentsply Sirona for Investor Rights

Updated Category News Views 91

Important Notice for Dentsply Sirona Inc. Shareholders The Gross Law Firm has issued a notice for shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who acquired shares during the recently identified class period are encouraged to reach out regarding the opportunity to be appointed as lead plaintiff. Securing this position is not a prerequisite for...

Continue Reading
Major Insider Sale by James Davis at American Woodmark Revealed

Updated Category News Views 447

Insider Activity Spotlight on American Woodmark James Davis, a Board Member of American Woodmark (NASDAQ: AMWD), has made headlines recently by selling a significant number of shares, which has sparked various reactions in the market. Understanding Recent Transactions: In a recent SEC filing, it was reported that DAVIS sold 1,250 shares of American Woodmark, amounting to...

Continue Reading
Ivybrook's $5K Franchise Incentive Targets Educators

Updated Category News Views 28

Franchise ownership might just feel within reach for educators eying a new chapter, thanks to Ivybrook Academy’s fresh incentive. The renowned half-day preschool franchise is now offering a cool $5,000 cut off the initial franchise fee to educators diving into franchise ownership. It’s a nod to those who spend their days molding young minds. Opening Doors for...

Continue Reading
NOAA Taps ICEYE US for Game-Changing SAR Satellite Data

Updated Category News Views 61

The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...

Continue Reading